Homepage
Medication Guide
Side Effects of Pirtobrutinib
Pirtobrutinib is a novel Bruton’s Tyrosine Kinase (BTK) inhibitor. It has been approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL) in patients who have received at least 2 lin...
506
Thursday, December 4th, 2025, 11:14
What Are the Precautions for Pirtobrutinib Administration?
Pirtobrutinib is a kinase inhibitor. It is used to treat relapsed or refractory mantle cell lymphoma (MCL) in patients who have previously received at least two lines of systemic therapy (including a ...
504
Thursday, December 4th, 2025, 11:11
Dosage and Administration of Pirtobrutinib
Pirtobrutinib is a novel kinase inhibitor that received its first approval in the United States in 2023. As a highly selective BTK inhibitor, it has demonstrated favorable efficacy in the treatment of...
508
Thursday, December 4th, 2025, 11:09
What Are the Indications for Pirtobrutinib?
Pirtobrutinib is a novel kinase inhibitor that received its first approval in the United States in 2023. As a non-covalent inhibitor of Bruton's Tyrosine Kinase (BTK), it demonstrates unique advan...
509
Thursday, December 4th, 2025, 11:06
What Are the Purchase Channels for Pirtobrutinib?
Pirtobrutinib is a novel BTK kinase inhibitor. It provides a new treatment option for patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two lines of...
506
Thursday, December 4th, 2025, 11:00
Side Effects of Capivasertib
Capivasertib is a next-generation AKT kinase inhibitor. Used in combination with fulvestrant, it treats HR-positive, HER2-negative advanced breast cancer harboring PIK3CA/AKT1/PTEN mutations. While de...
510
Thursday, December 4th, 2025, 10:45
What Are the Precautions for Capivasertib Administration?
Capivasertib is a kinase inhibitor. It is used in combination with fulvestrant for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer harboring PIK3CA/AKT1/PTEN gene muta...
510
Thursday, December 4th, 2025, 10:42
Dosage and Administration of Capivasertib
Capivasertib is a novel kinase inhibitor that received its first approval in the United States in 2023. As a precision therapy targeting specific gene mutations, it has demonstrated favorable efficacy...
514
Thursday, December 4th, 2025, 10:05
What Are the Indications of Capivasertib?
Capivasertib is a kinase inhibitor developed by AstraZeneca, which was first approved for marketing in the United States in 2023. When used in combination with fulvestrant, this medication is indicate...
508
Wednesday, December 3rd, 2025, 10:27
What Are the Purchase Channels for Capivasertib?
Capivasertib is an AKT kinase inhibitor, providing a new treatment option for patients with HR-positive, HER2-negative advanced breast cancer. As a prescription medication, understanding its standardi...
507
Wednesday, December 3rd, 2025, 10:22
44 / 214
2139 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved